Insider Trading Arrangements |
3 Months Ended | 6 Months Ended |
|---|---|---|
|
Jun. 30, 2024
shares
|
Jun. 30, 2024
shares
|
|
| Trading Arrangements, by Individual | ||
| Non-Rule 10b5-1 Arrangement Adopted | false | |
| Rule 10b5-1 Arrangement Terminated | false | |
| Non-Rule 10b5-1 Arrangement Terminated | false | |
| Michael I. Halstead [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | •On May 22, 2024, Sharon Mates, Ph.D., Chairman and Chief Executive Officer, adopted a Rule 10b5-1 Sales Plan having an end date of December 31, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 286,998 shares of our common stock, including the potential sale of up to 216,998 shares of our common stock upon the exercise of stock options with an exercise expiration date of January 1, 2025. On May 28, 2024, Dr. Mates adopted a subsequently commencing Rule 10b5-1 Sales Plan with a start date of January 2, 2025 and an end date of March 31, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 96,247 shares of our common stock upon the vesting of restricted stock units and (ii) all shares issuable upon the vesting of performance restricted stock units for up to 30,847 shares of our common stock at maximum achievement of the performance vesting conditions. •On June 4, 2024, Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer, adopted a Rule 10b5-1 Sales Plan having an end date of March 31, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of an indeterminate number of shares of our common stock sufficient to cover Dr. Durgam’s tax liability (i) upon the vesting of restricted stock units for an aggregate of 29,220 shares of our common stock and (ii) upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions. •On June 7, 2024, Mark Neumann, Executive Vice President, Chief Commercial Officer, adopted a Rule 10b5-1 Sales Plan having an end date of March 31, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 29,200 shares of our common stock upon the vesting of restricted stock units and (ii) all shares issuable upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions.
|
|
| Sharon Mates, Ph.D [Member] | ||
| Trading Arrangements, by Individual | ||
| Arrangement Duration | 223 days | |
| Suresh Durgam, M.D [Member] | ||
| Trading Arrangements, by Individual | ||
| Name | Suresh Durgam, M.D | |
| Title | Executive Vice President, Chief Medical Officer, | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | June 4, 2024 | |
| Expiration Date | March 31, 2025 | |
| Arrangement Duration | 300 days | |
| Aggregate Available | 29,220 | 29,220 |
| Mark Neumann [Member] | ||
| Trading Arrangements, by Individual | ||
| Name | Mark Neumann | |
| Title | Executive Vice President, Chief Commercial Officer, | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | June 7, 2024 | |
| Expiration Date | March 31, 2025 | |
| Arrangement Duration | 480 days | |
| Aggregate Available | 29,200 | 29,200 |
| Dr. Mates [Member] | ||
| Trading Arrangements, by Individual | ||
| Arrangement Duration | 88 days | |
| Sharon Mates, Ph.D Trading Arrangement, May 22 Plan [Member] | Sharon Mates, Ph.D [Member] | ||
| Trading Arrangements, by Individual | ||
| Name | Sharon Mates, Ph.D. | |
| Title | Chairman and Chief Executive Officer, | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | May 22, 2024 | |
| Expiration Date | December 31, 2024 | |
| Aggregate Available | 286,998 | 286,998 |
| Sharon Mates, Ph.D Trading Arrangement, May 28 Plan [Member] | Sharon Mates, Ph.D [Member] | ||
| Trading Arrangements, by Individual | ||
| Name | Dr. Mates | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | May 28, 2024 | |
| Expiration Date | March 31, 2025 | |
| Aggregate Available | 96,247 | 96,247 |